In Brief: Haemonetics' John White
This article was originally published in The Gray Sheet
Executive Summary
Haemonetics' John White: Chairman and CEO steps down Jan. 27 at the request of the board of directors, which cites a leveling off in the blood products and processing systems maker's financial performance over the last two years. White is succeeded as CEO by James Peterson, formerly vice chairman and president of Haemonetics International. Succeeding White as chairman is Sir Stuart Burgess, who has been a board member since 1992 and is former CEO of Amersham International. White, who had been CEO since 1985, "helped to grow the company from a $32 mil. business to a global firm with over $300 mil. in revenues," the firm notes. For the three months ended Dec. 27, net revenues decreased 1% to $75.8 mil. Excluding the effect of a $25.2 mil. restructuring charge, net income declined 33% to $4.7 mil...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.